Essential Principles for Medical Devices in Australia

1. Key takeaways

The Essential Principles are the Australian counterpart of general safety and performance requirements, located in Schedule 1 of the Therapeutic Goods (Medical Devices) Regulations 2002, currently comprising items 1–15 together with the inserted items 13A, 13B, and 13C, for a total of 18 clause units. Compliance is judged on an all-or-nothing standard: a breach of any single item means non-compliance with the Essential Principles as a whole. This structural feature shapes everything about how evidence should be assembled, because there is no partial credit in the statutory test. A device whose file is strong on most items but silent on one item is, in legal terms, in exactly the same position as a device with no evidence at all, and the consequences flow through to conformity assessment certificates and ARTG entry alike. The practical consequence is that evidence collection should be sequenced by risk of omission rather than by document convenience, with the items most often left uncovered addressed first, so that the file converges on completeness rather than on volume.

2. Legal basis

1. Therapeutic Goods (Medical Devices) Regulations 2002 (F2002B00237, compilation F2026C00883): the Essential Principles sit in Schedule 1, introduced by regulation 2.1; Part 1 general principles, items 1–6; Part 2 other principles, items 7–15.
2. The compliance determination provision: section 41BH(1)–(3) of the Therapeutic Goods Act 1989 (Act No. 21, 1990) — a device is compliant only if it does not contravene any Essential Principle; where the device complies with a medical device standard applicable to it, compliance with the parts covered by that standard may be taken as established (Part 411 excepted).
3. Newly added clause units: 13A — implantable and active implantable devices must be supplied with patient information (cl 13A.1–13A.4); 13B — software version numbers and build numbers (Software — version numbers and build numbers), added by the Therapeutic Goods Legislation Amendment (2019 Measures No. 1) Regulations 2019 (F2019L01660), with the relevant parts effective from 25 February 2021.
4. 13C — Rules for UDI medical devices (cl 13C.1–13C.5), introduced by the Therapeutic Goods Legislation Amendment (Australian Unique Device Identification Database and Other Measures) Regulations 2025 (F2025L00414), effective from 25 March 2025; item 13C.3 requires other device-associated data to be entered into AusUDID, and 13C.5 requires the UDI-DI and UDI-PI to be directly marked on the device itself.
5. Stand-alone principles: item 14 requires every device to have clinical evidence commensurate with its use and classification; item 15 applies to IVDs only.
6. Control of materials of animal, microbial, or recombinant origin: Schedule 1, item 8.2.

3. Expert insights

Insight 1: Item 13C writes a database obligation into the Essential Principles. UDI data that is absent from AusUDID, inaccurate, or not directly marked is, in character, a breach of the Essential Principles rather than a labelling defect. The consequence tier runs straight to suspension or cancellation of the ARTG entry, which is the fundamental reason a UDI programme must be managed as a compliance project and not as an IT project. Treating the data work as an engineering side-task understates both the legal exposure and the cross-functional coordination it requires, since regulatory, manufacturing, labelling, and IT teams all hold pieces of the required data.

Insight 2: Item 13B makes version numbers regulated information. Software version numbers and build numbers are singled out as an Essential Principle, which means version management is no longer an internal engineering matter; a missing version identifier can be cited directly as a non-conformity during conformity assessment. The practical implication is that release processes must produce records that a reviewer can read without translation, and that the numbering scheme itself must be stable and documented, because an undocumented scheme is functionally equivalent to no scheme when evidence is examined.

Insight 3: The all-or-nothing determination compresses the room for negotiation. Under the structure of section 41BH there is no intermediate state of being mostly compliant. When preparing technical documentation we work through the TGA Essential Principles checklist item by item and close each one, rather than spreading effort evenly across chapters. This sequencing matters because gaps discovered late in the process force rework of linked sections, while gaps found early can be closed while the evidence base is still being assembled, at a fraction of the cost.

4. Practical recommendations

1. Build an Essential Principles cross-reference matrix that, for each of the 18 clause units, names the evidence file, its storage location, and the responsible person, so that completeness can be verified at a glance rather than reconstructed from memory.
2. For implantable and software products, prepare the evidence for items 13A and 13B as stand-alone volumes, separate from the general technical documentation, to avoid retrieval difficulties when an assessor looks for them mid-review.
3. For the UDI-related items (13.5, 13.6, 13A.2, 13C.1–13C.5), plan backwards from the staged mandatory dates, prioritising 1 July 2026 for Class III and Class IIb devices, and assign ownership of each milestone before the plan is circulated.
4. When citing harmonised standards, first confirm whether the standard covers the entire content of the particular clause, so that partial coverage is never presented as full compliance and later exposed as a gap. Recording the exact clauses a standard is relied upon for, rather than citing the standard wholesale, keeps the reliance transparent and defensible.

5. Verification checklist

• □ The cross-reference matrix covers all 18 clause units of Schedule 1
• □ Compliance is confirmed to be judged under the all-or-nothing standard of section 41BH(1)–(3)
• □ Implantable products have the item 13A patient information evidence prepared
• □ Software products have the item 13B version number and build number evidence prepared
• □ The UDI-related item 13C clauses have been planned backwards from the staged mandatory dates
• □ Cited standards have been verified as covering the complete content of the relevant clauses

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages TGA inclusion and ARTG listing applications, coordinates conformity assessment evidence, and supports post-market vigilance obligations. Business enquiries: info@grzan.cn